Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is the biotech world. Maybe they should of given President Carter a little chemo instead of immunotherapy! I wonder how that would of turned out but never mind we don’t need new technology the current stuff is just fine!
LR news flash ipix signed a licensing deal which will provide for non dilutive funding which in turn will allow them to advance their drugs with the new delivery systems. This is biotech...it’s a risk... sometimes it works sometimes it doesn’t. I would prefer the trials to be done with the most advanced delivery systems.
LR news flash ipix signed a licensing deal which will provide for non dilutive funding which in turn will allow them to advance their drugs with the new delivery systems. This is biotech...it’s a risk... sometimes it works sometimes it doesn’t. I would prefer the trials to be done with the most advanced delivery systems.
Fortunately we aren’t in your world we are in the fast paced world of biotech where thing are changing daily. Get with the program. Ipix is changing it’s delivery method because the new technology is better. Period. End of discussion.
Is this really a legitimate comment? “Why "transition" to new formulations when the originals were, as investors were led to believe, stellar? Fix a leaking roof before you replace any resultant ceiling damage. The ceiling wasn't damaged, was it?” You transition because the new technology is better for the potential patients!
Please reread. “Bertolino continued: “The Alfasigma licensing agreement, importantly, enables us to access non-dilutive capital immediately and potentially into the future, via structured milestone-based payments and royalties. Equally important, we can now dedicate further internal resources to moving our clinical portfolio ahead—developing novel oral medications for hard-to-treat diseases like IBD, Oral Mucositis and Cancer.”
Please read:
“Bertolino continued: “The Alfasigma licensing agreement, importantly, enables us to access non-dilutive capital immediately and potentially into the future, via structured milestone-based payments and royalties”
Please reread: “Successfully completing additional strategic alliances and licensing deals remains a primary objective, towards which we are making notable progress, with multiple active advanced-stage negotiations ongoing”
Kevetrin
Oncology
June 2019: Abstract published—“Kevetrin Dampens MYC Expression and Cellular Metabolism in Acute Myeloid Leukemia”—in collaboration with independent cancer researchers; presented at the European Hematological Association (EHA) 2019 Annual Meeting. Results showed Kevetrin alters cellular metabolism and several key genes, including MYC, which when dysfunctional is implicated in many types of cancers. These results further support Kevetrin’s treatment potential in AML, especially among those patients carrying p53 mutations for whom few therapeutic options exist.
Try reading!
Bertolino continued: “The Alfasigma licensing agreement, importantly, enables us to access non-dilutive capital immediately and potentially into the future, Non-dilutive financing! That’s the ticket!
Exactly! Third party validation, money in the bank and the future for more trials is secure.
I think you as a shareholder( is it millions or billions I can’t remember your last share count?) should contact the company and get to the bottom of the term sheet issue. I am sure your advice and counsel would be appreciated.
That’s about par for the course for someone who’s life work consists of being that irritating pebble in your shoe!
Plagiarism is a sign of desperation.
Interesting article for all those who say that people aren’t trying to manipulate markets and investments all the time.
https://www.zerohedge.com/news/2019-06-25/merrill-lynch-caught-criminally-manipulating-precious-metals-market-thousands-times
I loved the dirt one!
I am not sure what the point of the article was. Seems like it was another article about something maybe could be really super great we just need to study it.
“While there is limited data to suggest Cannabidiol can kill bacteria, the drug has not been thoroughly investigated for its potential as an antibiotic. ”
Lmao! At the time we were running the trial cubican was bought for $10b!
Couldn’t agree more
That’s complete bs!
Agreed! This is a huge problem in orthopedics.
There are plenty of public companies(big and small), who have the big name boards and fancy accounting firms, that have had serious leadership issues or bankruptcy.
The truth is no one believes you
No thanks. Your credibility is shot!
I agree. One of the things that’s different about this term sheet situation is that we are not waiting or dependent on an ongoing trial. The term sheet was signed based on the the trial phase 2 trial. Of course we don’t know the terms but I believe this deal will happen.
Ipix is creating a lot of reality changing! No one saw a possible IBD deal. My bet is that management makes a deal soon. Of course this will cause more reality changing but that’s alright we are getting used to it! Lol
“All but the most anemic deal provides third party validation, demonstrates BP interest, restores credibility to management, provides balance sheet relief, and removes funding pressures on the stock. That makes it easier for the market to look forward a couple years rather than a couple months which allows for appreciation based on the pipeline potential.“ I agree completely. None of the “smart” people ever said anything about a IBD deal potentially being our being our 1st deal, just goes to show you what they know.
Huge $$ in IBD!!
Great news!! Go Ipix!
Carnage! LMFAO! If you had told anyone on this board Monday morning that we would be at .345 on Wednesday they would of thought you were crazy!
Nice call! Dud
Useless information about a company other than ipix.
“I think that I have made such posts when appropriate” please show 2 examples.
Thanks for nailing down the very obvious fact( from your post) that the economics of a new antibiotic are less than the revenue potential of anti inflammatory applications.
Crickets!
Didn’t you read the article about the antibiotic company that just went BK! There is much more money in anti inflammatory applications.
This is Exactly why Leo wanted to go after OM and IBD. You have illustrated the pointed perfectly.
He is not a doctor.
WTF! Those companies were mentioned already. Why would they need to mention it again? Did they violate a rule or law by not mentioning them?